Hostname: page-component-848d4c4894-m9kch Total loading time: 0 Render date: 2024-05-01T09:04:56.328Z Has data issue: false hasContentIssue false
  • English
  • Français

Positive and Negative Schizophrenia Symptoms and the Role of Dopamine

Published online by Cambridge University Press:  29 January 2018

T. J. Crow
T. J. Crow*
Affiliation:
Division of Psychiatry, Clinical Research Centre, Northwick Park Hospital, Watford Road, Harrow, Middlesex HA1 3UJ
Get access Rights & Permissions [Opens in a new window]

Extract

Presumably one function of an hypothesis is to provoke further thought and observation. Therefore, I welcome the critical comments of Ashcroft and colleagues (Journal, March 1981, 138, 268–9) on my suggestion concerning the relationship between dopaminergic disturbances and the positive and negative symptoms of schizophrenia (Crow, 1980a, b). However, I think they have misunderstood the proposal and have underestimated some of the relevant evidence. I believe the evidence for two processes is more compelling than they have conceded and I note that in their own hypothesis they have introduced two factors to account for phenomena that both Mackay (1980) and I regard as a problem for the simple dopamine theory.

Type
Riposte
Information
The British Journal of Psychiatry , Volume 139 , Issue 3 , September 1981 , pp. 251 - 254
Copyright
Copyright © Royal College of Psychiatrists, 1981 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Angrist, B. M., Rotrosen, J. & Gershon, S. (1980) Differential effects of amphetamine and neuroleptics on negative vs positive symptoms in schizophrenia. Psychopharmacology, 72, 17—19.Google Scholar
Casey, J. F., Bennett, I. F., Lindley, C. J., Hollister, L. E., Gordon, M. H. & Springer, N. N. (1960) Drug therapy in schizophrenia. A controlled study of the relative effectiveness of chlorpromazine, promazine, phenobarbital and placebo. Archives of General Psychiatry, 2, 210–20.Google Scholar
Crow, T. J. (1980a) Molecular pathology of schizophrenia: more than one disease process? British Medical Journal, 280, 66–8.CrossRefGoogle ScholarPubMed
Crow, T. J. (1980b) Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry, 137, 383–86.Google Scholar
Crow, T. J., Owen, F., Cross, A. J., Ferrier, I. N., Johnstone, E. C., McCreadie, R. G., Owens, D. G. C. & Poulter, M. (1981) Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: evidence that an increase in D2 receptors is associated with the type I syndrome. In Transmitter Biochemistry of Human Brain Tissue (eds. Usdin, E. and Riederer, P.) (in press).Google Scholar
Donnelly, E. F., Weinberger, D. R., Waldman, I. N. & Wyatt, R. J. (1980) Cognitive impairment associated with morphological brain abnormalities on computed tomography in chronic schizophrenic patients. Journal of Nervous, Mental Disorders, 168, 305–8.Google Scholar
Frith, C. D. (1977) Two kinds of cognitive deficit associated with chronic schizophrenia. Psychological Medicine, 7, 171–3.Google Scholar
Golden, C. J., Moses, J. A., Zelakowski, R., Graber, R., Zatz, L. M., Horvath, T. B. & Berger, P. A. (1980) Cerebral ventricular size and neuropsychological impairment in young chronic schizophrenics. Archives General Psychiatry, 37, 619–23.Google Scholar
Johnstone, E. C., Crow, T. J., Frith, C. D., Husband, J. & Kreel, L. (1976) Cerebral ventricular size and cognitive impairment in chronic schizophrenia. Lancet, ii, 924–6.Google Scholar
Johnstone, E. C., Crow, T. J., Frith, C. D., Stevens, M., Kreel, L. & Husband, J. (1978a) The dementia of dementia praecox. Acta Psychiatrica Scandinavica, 57, 305–24.Google Scholar
Johnstone, E. C., Crow, T. J., Frith, C. D., Carney, M. W. P. & Price, J. S. (1978b) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet, i, 848–51.Google Scholar
Kornetsky, C. (1976) Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Archives of General Psychiatry, 33, 1425–8.CrossRefGoogle ScholarPubMed
Mackay, A. V. P. (1980) Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry, 137, 379–83.Google Scholar
Owen, F., Cross, A. J., Crow, T. J., Longden, A., Poulter, M. & Riley, G. J. (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet, ii, 223–5.Google Scholar
Owens, D. G. C. & Johnstone, E. C. (1980) The disabilities of chronic schizophrenia—their nature and the factors contributing to their development. British Journal of Psychiatry, 136, 384–95.Google Scholar
Quitkin, F., Rifkin, A. & Klein, D. F. (1976) Neurologic soft signs in schizophrenia and character disorder. Archives of General Psychiatry, 33, 845–53.Google Scholar
Randrup, A., Munkvad, I., Fog, R., Gerlach, J., Molander, L., Kjellberg, B. & Scheel-Kruger, J. (1975) Mania, depression and brain dopamine. In Current Developments in Psychopharmacology, 2, 206–48 (eds. Essman, W. B. and Valzelli, L.). New York: Spectrum.Google Scholar
Rieder, R. O., Donnelly, E. F., Herdt, J. R. & Waldman, N. (1979) Sulcal prominence in young chronic schizophrenic patients: CT scan findings associated with impairment on neuropsychological tests. Psychiatric Research, 1, 1—8.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.